[{"AccountsPayableCurrent_0_Q2_USD":10065000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":7948000.0,"IncreaseDecreaseInPrepaidExpensesOther_2_Q2_USD":6039000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":9614000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":26757000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":16585000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":31861000.0,"IncreaseDecreaseInOtherOperatingAssets_2_Q2_USD":73000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-12120000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":19927000.0,"PaymentsToAcquireProductiveAssets_2_Q2_USD":3322000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":105568000.0,"ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2_Q2_USD":19900000.0,"ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1_Q2_USD":5000000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q2_USD":1144000.0,"OtherPrepaidExpenseCurrent_0_Q2_USD":13124000.0,"IncomeLossFromEquityMethodInvestments_1_Q2_USD":21381000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":135000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-232000.0,"RepaymentsOfNotesPayable_2_Q2_USD":235347000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":936000.0,"ProceedsFromIssuanceOfLongTermDebt_2_Q2_USD":380000000.0,"IncreaseDecreaseInIncomeTaxesReceivable_2_Q2_USD":300000.0,"IncreaseDecreaseInInterestPayableNet_2_Q2_USD":-1957000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-145805000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-63119000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":7018000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-5753000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":61676000.0,"IncomeLossFromEquityMethodInvestments_2_Q2_USD":34896000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_Q2_USD":31861000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":16585000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":284000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":34870000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":15008000.0,"RestrictedCashNoncurrent_0_Q2_USD":833000.0,"RestrictedCash_0_Q2_USD":833000.0,"ProceedsFromStockPlans_2_Q2_USD":2545000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2_Q2_USD":155703000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":280495000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":7948000.0,"PaymentsOfLoanCosts_2_Q2_USD":11470000.0,"OtherNoncashIncomeExpense_2_Q2_USD":4000.0,"OtherDepreciationAndAmortization_2_Q2_USD":4034000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":45184000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":47631000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":8741000.0,"IncreaseDecreaseInOtherNoncurrentLiabilities_2_Q2_USD":175000.0,"IncomeTaxesReceivableNoncurrent_0_Q2_USD":3986000.0,"FinanceLeaseRightOfUseAssetAmortization_2_Q2_USD":1420000.0,"DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_0_Q2_USD":0.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0_Q2_USD":3000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0_Q2_USD":59965000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_0_Q2_USD":3000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0_Q2_USD":59965000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":1154000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":25062000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":46671000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":333605000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":384237000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":383957000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":4000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":63275000.0,"StockIssuedDuringPeriodValueNewIssues_2_Q2_USD":139915000.0,"PaymentsOfDebtIssuanceCosts_2_Q2_USD":5326000.0,"OtherAssetsNoncurrent_0_Q2_USD":1508000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1394540000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":14433000.0,"ProceedsFromSaleOfPropertyPlantAndEquipment_2_Q2_USD":1000.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":139915000.0,"NetIncomeLoss_2_Q2_USD":-145940000.0,"NetIncomeLoss_1_Q2_USD":-62887000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-108447000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-108186000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":263305000.0,"LiabilitiesCurrent_0_Q2_USD":106574000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":564330000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":6012000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":186000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":39000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-145754000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-62848000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-2.39,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-1.0,"DueFromRelatedPartiesCurrent_0_Q2_USD":35509000.0,"CommonStockValue_0_Q2_USD":1000.0,"CommonStockSharesOutstanding_0_Q2_shares":63515000.0,"CommonStockSharesIssued_0_Q2_shares":63515000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":104735000.0,"AssetsCurrent_0_Q2_USD":498386000.0,"Assets_0_Q2_USD":564330000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":12417000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":12389000.0,"AdditionalPaidInCapital_0_Q2_USD":1191923000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":280000.0,"StockholdersEquity_0_Q2_USD":-202336000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q2_USD":2545000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":62861000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"OtherNonoperatingIncomeExpense_2_Q2_USD":798000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-662000.0,"GainsLossesOnExtinguishmentOfDebt_2_Q2_USD":-15464000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":61162000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":62861000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_2_Q2_USD":936000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":733000.0,"ShareBasedCompensation_2_Q2_USD":31861000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":51105000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":24780000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":128417000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":62404000.0,"PreferredStockValue_0_Q2_USD":0.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PreferredStockSharesAuthorized_0_Q2_shares":230000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0,"OperatingIncomeLoss_2_Q2_USD":-144652000.0,"OperatingIncomeLoss_1_Q2_USD":-72176000.0,"OperatingExpenses_2_Q2_USD":179522000.0,"OperatingExpenses_1_Q2_USD":87184000.0,"InterestPayableCurrent_0_Q2_USD":3702000.0,"InterestPaidNet_2_Q2_USD":20287000.0,"InterestExpense_2_Q2_USD":21332000.0,"InterestExpense_1_Q2_USD":11391000.0,"IncomeTaxesPaidNet_2_Q2_USD":14000.0,"ConvertibleLongTermNotesPayable_0_Q2_USD":226427000.0,"CommonStockSharesAuthorized_0_Q2_shares":200000000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":61162000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2_Q2_USD":2545000.0,"Ticker":"TBPH","CIK":"1583107","name":"THERAVANCE BIOPHARMA, INC.","OfficialName":"Theravance Biopharma Inc. Ordinary Shares","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"688048421.0","Country":"Cayman Islands","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200810"}]